Scoping review of intervention studies to improve opioid and alcohol use outcomes and links to care following inpatient detoxification

References

• Acevedo A, Lee MT, Garnick DW, Horgan CM, Ritter GA, Panas L, Campbell K, Bean-Mortinson J. 2018. Agency-level financial incentives and electronic reminders to improve continuity of care after discharge from residential treatment and detoxification. Drug Alcohol Depend. 183:192–200.
   PubMed Web of Science ®Google Scholar
• Amodeo M, Lundgren L, Chassler D, Witas J. 2008. High-frequency users of detoxification: who are they? Subst Use Misuse. 43(7):839–849.
   PubMed Web of Science ®Google Scholar
• Ashford RD, Brown A, Brown T, Callis J, Cleveland HH, Eisenhart E, Groover H, Hayes N, Johnston T, Kimball T, et al. 2019. Defining and operationalizing the phenomena of recovery: a working definition from the recovery science research collaborative. Addict Res Theory. 27(3):179–188.
   Web of Science ®Google Scholar
• Baltieri DA, De Andrade AG. 2004. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol. 65(1):136–139.
   PubMed Web of Science ®Google Scholar
• Beaini AY, Johnson TS, Langstaff P, Carr MP, Crossfield JN, Sweeney RC. 2000. A compressed opiate detoxification regime with naltrexone maintenance: patient tolerance, risk assessment and abstinence rates. Addict Biol. 5(4):451–462.
   PubMed Web of Science ®Google Scholar
• Bell JR, Young MR, Masterman SC, Mattick RP, Bammer G. 1999. A pilot study of naltrexone‐accelerated detoxification in opioid dependence. Med J Aust. 171(1):26–30.
   PubMed Web of Science ®Google Scholar
• Bender S, Scherbaum N, Soyka M, Ruther E, Mann K, Gastpar M. 2007. The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: A randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. Int J Neuropsychopharm. 10(05):653–660.
   PubMedGoogle Scholar
• Berman AH, Forsberg L, Durbeej N, Kallmen H, Hermansson U. 2010. Single-session motivational interviewing for drug detoxification inpatients: Effects on self-efficacy, stages of change and substance use. Subst Use Misuse. 45(3):384–402.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Sullivan MA, Cheng WY, Carpenter KM, Mariani JJ, Levin FR, Raby WN, Nunes EV. 2011. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend. 119(1-2):e23–9.
   PubMedGoogle Scholar
• Bisaga A, Sullivan MA, Glass A, Mishlen K, Carpenter KM, Mariani JJ, Levin FR, Nunes EV. 2014. A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence. J Subst Abuse Treat. 46(5):546–552.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Sullivan MA, Glass A, Mishlen K, Pavlicova M, Haney M, Raby WN, Levin FR, Carpenter KM, Mariani JJ, et al. 2015. The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend. 154:38–45.
   PubMed Web of Science ®Google Scholar
• Blondell RD, Frydrych LM, Arber BC, Bashaw HL, Vexler A, Purdy CH, Sawyer RM, Okazaki S. 2008. A randomized trial of extended buprenorphine detoxification for opioid dependency. J Addict Med. 2(3):139–146.
   PubMed Web of Science ®Google Scholar
• Blondell RD, Frydrych LM, Jaanimagi U, Ashrafioun L, Homish GG, Foschio EM, Bashaw HL. 2011. A randomized trial of two behavioral interventions to improve outcomes following inpatient detoxification for alcohol dependence. J Addict Dis. 30(2):136–148.
   PubMed Web of Science ®Google Scholar
• Bolek S, Yargic I, Ekinci O. 2016. The effects of Buprenorphine/Naloxone maintenance treatment on the quality of life, substance use and functionality in opiate dependence: A follow-up study. Klinik Psikofarmakoloji Bülteni-Bulletin of Clin Psychopharmacol. 26(2):141–151.
   Web of Science ®Google Scholar
• Brigham GS, Amass L, Winhusen T, Harrer JM, Pelt A. 2007. Using buprenorphine short-term taper to facilitate early treatment engagement. J Subst Abuse Treat. 32(4):349–356.
   PubMed Web of Science ®Google Scholar
• Brigham GS, Slesnick N, Winhusen TM, Lewis DF, Guo X, Somoza E. 2014. A randomized pilot clinical trial to evaluate the efficacy of Community Reinforcement and Family Training for Treatment Retention (CRAFT-T) for improving outcomes for patients completing opioid detoxification. Drug Alcohol Depend. 138:240–243.
   PubMed Web of Science ®Google Scholar
• Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR. 2013. Power failure: Why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci. 14(5):365–376.
   PubMed Web of Science ®Google Scholar
• Caldiero RM, Parran TV, Jr., Adelman CL, Piche B. 2006. Inpatient initiation of buprenorphine maintenance vs. detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict. 15(1):1–7.
   PubMed Web of Science ®Google Scholar
• Campbell BK, Fuller BE, Lee ES, Tillotson C, Woelfel T, Jenkins L, Robinson J, Booth RE, McCarty D. 2009. Facilitating outpatient treatment entry following detoxification for injection drug use: a multisite test of three interventions. Psychol Addict Behav. 23(2):260–270.
   PubMed Web of Science ®Google Scholar
• Carlson RW, Kumar NN, Wong-Mckinstry E, Ayyagari S, Puri N, Jackson FK, Shashikumar S. 2012. Alcohol withdrawal syndrome. Crit Care Clin. 28(4):549–585.
   PubMed Web of Science ®Google Scholar
• Carroll KM, Weiss RD. 2017. The role of behavioral interventions in buprenorphine maintenance treatment: a review. AJP. 174(8):738–747.
   Google Scholar
• Chalana H, Kundal T, Gupta V, Malhari AS. 2016. Predictors of relapse after inpatient opioid detoxification during 1-year follow-up. J Addict. 2016:7620860.
   PubMedGoogle Scholar
• Chang G, Raffi E, Tang M, Fernando GI, Zucker J, Schein AZ. 2016. High utilization of inpatient detoxification: predictors among US veterans. Am J Drug Alcohol Abuse. 42(3):279–286.
   PubMed Web of Science ®Google Scholar
• Chih M. 2014. Exploring the use patterns of a mobile health application for alcohol addiction before the initial lapse after detoxification. AMIA Annu Symp Proc. 2014:385–394.
   PubMedGoogle Scholar
• Chutuape MA, Katz EC, Stitzer ML. 2001. Methods for enhancing transition of substance dependent patients from inpatient to outpatient treatment. Drug Alcohol Depend. 61(2):137–143.
   PubMed Web of Science ®Google Scholar
• Chutuape MA, Silverman K, Stitzer M. 1999. Contingent reinforcement sustains post-detoxification abstinence from multiple drugs: A preliminary study with methadone patients. Drug Alcohol Depend. 54(1):69–81.
   PubMed Web of Science ®Google Scholar
• Collins ED, Horton T, Reinke K, Amass L, Nunes EV. 2007. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation. J Subst Abuse Treat. 32(2):167–175.
   PubMed Web of Science ®Google Scholar
• Collins ED, Kleber HD, Whittington RA, Heitler NE. 2005. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. Jama. 294(8):903–913.
   PubMed Web of Science ®Google Scholar
• Colquhoun RM. 2013. Open label trial of naltrexone implants: measuring blood serum levels of naltrexone. Subst Abuse. 7:75–84.
   PubMedGoogle Scholar
• De Jong CA, Laheij RJ, Krabbe PF. 2005. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: A randomized controlled trial. Addict. 100(2):206–215.
   PubMed Web of Science ®Google Scholar
• Del Felice A, Bellamoli E, Formaggio E, Manganotti P, Masiero S, Cuoghi G, Rimondo C, Genetti B, Sperotto M, Corso F, et al. 2016. Neurophysiological, psychological and behavioural correlates of rTMS treatment in alcohol dependence. Drug Alcohol Depend. 158:147–153.
   PubMed Web of Science ®Google Scholar
• Department of Veterans Affairs and Department of Defense 2009. VA/DoD clinical practice guideline for management of substance use disorders (v. 2). Washington (DC): The Management of SUD Working Group.
   Google Scholar
• Diehl A, Ulmer L, Mutschler J, Herre H, Krumm B, Croissant B, Mann K, Kiefer F. 2010. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol Alcohol. 45(3):271–277.
   PubMed Web of Science ®Google Scholar
• Donovan DM, Knox PC, Skytta JA, Blayney JA, DiCenzo J. 2013. Buprenorphine from detox and beyond: Preliminary evaluation of a pilot program to increase heroin dependent individuals' engagement in a full continuum of care. J Subst Abuse Treat. 44(4):426–432.
   PubMed Web of Science ®Google Scholar
• Dunn KE, Defulio A, Everly JJ, Donlin WD, Aklin WM, Nuzzo PA, Leoutsakos JM, Umbricht A, Fingerhood M, Bigelow GE, et al. 2013. Employment-based reinforcement of adherence to oral naltrexone treatment in unemployed injection drug users. Exp Clin Psychopharmacol. 21(1):74–83.
   PubMed Web of Science ®Google Scholar
• Dunn KE, Fingerhood M, Wong CJ, Svikis DS, Nuzzo P, Silverman K. 2014. Employment-based abstinence reinforcement following inpatient detoxification in HIV-positive opioid and/or cocaine-dependent patients. Exp Clin Psychopharmacol. 22(1):75–85.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency 2006. Suboxone (buprenorphine/naloxone): An overview of Suboxone and why it is authorised in the EU (Last updated 6/2020). In. Amsterdam, The Netherlands.
   Google Scholar
• Everly JJ, DeFulio A, Koffarnus MN, Leoutsakos JM, Donlin WD, Aklin WM, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. 2011. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: A randomized controlled trial. Addict. 106(7):1309–1318.
   PubMed Web of Science ®Google Scholar
• Favrat B, Zimmermann G, Zullino D, Krenz S, Dorogy F, Muller J, Zwahlen A, Broers B, Besson J. 2006. Opioid antagonist detoxification under anaesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: a randomised clinical trial. Drug Alcohol Depend. 81(2):109–116.
   PubMed Web of Science ®Google Scholar
• Forozeshfard M, Hosseinzadeh Zoroufchi B, Saberi Zafarghandi MB, Bandari R, Foroutan B. 2014. Six-month follow-up study of ultrarapid opiate detoxification with naltrexone. Int J High Risk Behav Addict. 3(4):e20944.
   PubMedGoogle Scholar
• Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. 2008. Trazodone for sleep disturbance after alcohol detoxification: A double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 32(9):1652–1660.
   PubMed Web of Science ®Google Scholar
• Ganavadiya R, Chandrashekar BR, Singh P, Gupta R, Rana PT, Jain S. 2018. Knowledge, attitude, and practice among tobacco and alcohol addicts before and after psychological intervention in a de-addiction center at Madhya Pradesh, India. Ind Psychiatry J. 27(1):27–40.
   PubMedGoogle Scholar
• Gao G, Wang X, He S, Li W, Wang Q, Liang Q, Zhao Y, Hou F, Chen L, Li A. 2003. Clinical study for alleviating opiate drug psychological dependence by a method of ablating the nucleus accumbens with stereotactic surgery. Stereotact Funct Neurosurg. 81(1-4):96–104.
   PubMed Web of Science ®Google Scholar
• Ghitza UE, Gore-Langton RE, Lindblad R, Tai B. 2015. NIDA clinical trials network common data elements initiative: Advancing big-data addictive-disorders research. Front Psychiatry. 6:33.
   PubMed Web of Science ®Google Scholar
• Gruber K, Chutuape MA, Stitzer ML. 2000. Reinforcement-based intensive outpatient treatment for inner city opiate abusers: A short-term evaluation. Drug Alcohol Depend. 57(3):211–223.
   PubMed Web of Science ®Google Scholar
• Guo S, Jiang Z, Wu Y. 2001. Efficacy of naltrexone hydrochloride for preventing relapse among opiate-dependent patients after detoxification. Hong Kong J Psychiatry. 11:2–9.
   Google Scholar
• Haley SJ, Dugosh KL, Lynch KG. 2011. Performance contracting to engage detoxification-only patients into continued rehabilitation. J Subst Abuse Treat. 40(2):123–131.
   PubMed Web of Science ®Google Scholar
• Hines AL, Barrett ML, Joanna H, Steiner CA. 2014. Conditions With the largest number of adult hospital readmissions by payer, 2011. HCUP Statistical Brief #172. Rockville (MD): Agency for Healthcare Research and Quality.
   Google Scholar
• Hope AC. 1968. A simplified Monte Carlo significance test procedure. J R Stat Soc Series B. 30:582–598.
   Google Scholar
• Huang MC, Chen CH, Yu JM, Chen CC. 2005. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addict Biol. 10(3):289–292.
   PubMed Web of Science ®Google Scholar
• Humphreys K. 2016. Grappling with the generalizability crisis in addiction treatment research. Addict. 111(7):1141–1142.
   PubMed Web of Science ®Google Scholar
• Icro Maremmani AG, Bacciardi S, Rovai L, Rugani F, Massimetti E, Gazzarrini D, Dell'Osso L, Maremmani I. 2014. Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study. Int J Environ Res Public Health. 11(12):12983–12996.
   PubMed Web of Science ®Google Scholar
• Jarvis BP, Holtyn AF, DeFulio A, Koffarnus MN, Leoutsakos JS, Umbricht A, Fingerhood M, Bigelow GE, Silverman K. 2019. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: a randomized trial. Drug Alcohol Depend. 197:220–227.
   PubMed Web of Science ®Google Scholar
• John U, Veltrup C, Driessen M, Wetterling T, Dilling H. 2003. Motivational intervention: an individual counselling vs a group treatment approach for alcohol-dependent in-patients. Alcohol Alcohol. 38(3):263–269.
   PubMed Web of Science ®Google Scholar
• Jones HE, Wong CJ, Tuten M, Stitzer ML. 2005. Reinforcement-based therapy: 12-month evaluation of an outpatient drug-free treatment for heroin abusers. Drug Alcohol Depend. 79(2):119–128.
   PubMed Web of Science ®Google Scholar
• Kahler CW, Read JP, Ramsey SE, Stuart GL, McCrady BS, Brown RA. 2004. Motivational enhancement for 12-step involvement among patients undergoing alcohol detoxification. J Consult Clin Psychol. 72(4):736–741.
   PubMed Web of Science ®Google Scholar
• Kakko J, Svanborg KD, Kreek MJ, Heilig M. 2003. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. The Lancet. 361(9358):662–668.
   PubMed Web of Science ®Google Scholar
• Kelly JF, Mee-Lee D. 2018. Quality, accountability, and effectiveness in addiction treatment: The measurement-based practice model. In I. Danovitch & L. Mooney (eds.), The assessment and treatment of addiction: best practices and new frontiers. St. Louis (MO): Elsevier, p. 207–217.
   Google Scholar
• Kertesz SG, Horton NJ, Friedmann PD, Saitz R, Samet JH. 2003. Slowing the revolving door: Stabilization programs reduce homeless persons' substance use after detoxification. J Subst Abuse Treat. 24(3):197–207.
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kämpf P, Stracke R, Baehr M, Naber D, et al. 2003. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study. Arch Gen Psychiatry. 60(1):92–99.
   PubMed Web of Science ®Google Scholar
• Krabbe PF, Koning JP, Heinen N, Laheij RJ, van Cauter RM, De Jong CA. 2003. Rapid detoxification from opioid dependence under general anaesthesia versus standard methadone tapering: abstinence rates and withdrawal distress experiences. Addict Biol. 8(3):351–358.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. 2011. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 377(9776):1506–1513.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, et al. 2012. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 69(9):973–981.
   PubMed Web of Science ®Google Scholar
• Kuruvilla PK, Vijayakumar N, Jacob KS. 2004. A cohort study of male subjects attending an alcoholics anonymous program in India: One-year follow-up for sobriety. J Stud Alcohol. 65(4):546–549.
   PubMedGoogle Scholar
• Lee A, Tan S, Lim D, Winslow RM, Wong KE, Allen J, Hall W, Parker G. 2001. Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore. Drug Alcohol Rev. 20:193–199.
   Web of Science ®Google Scholar
• Leslie DL, Milchak W, Gastfriend DR, Herschman PL, Bixler EO, Velott DL, Meyer RE. 2015. Effects of injectable extended‐release naltrexone (XR‐NTX) for opioid dependence on residential rehabilitation outcomes and early follow‐up. Am J Addict. 24(3):265–270.
   PubMed Web of Science ®Google Scholar
• Liang L, Moore B, Soni A. 2006. National inpatient hospital costs: the most expensive conditions by payer, 2017: Statistical Brief# 261. Rockville (MD): Agency for Healthcare Research and Quality.
   Google Scholar
• Liebschutz JM, Crooks D, Herman D, Anderson B, Tsui J, Meshesha LZ, Dossabhoy S, Stein M. 2014. Buprenorphine treatment for hospitalized, opioid-dependent patients: A randomized clinical trial. JAMA Intern Med. 174(8):1369–1376.
   PubMed Web of Science ®Google Scholar
• Likhitsathian S, Uttawichai K, Booncharoen H, Wittayanookulluk A, Angkurawaranon C, Srisurapanont M. 2013. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. Drug Alcohol Depend. 133(2):440–446.
   PubMed Web of Science ®Google Scholar
• Liu S, Li L, Shen W, Shen X, Yang G, Zhou W. 2013. Scopolamine detoxification technique for heroin dependence: a randomized trial. CNS Drugs. 27(12):1093–1102.
   PubMed Web of Science ®Google Scholar
• Loeber S, Croissant B, Heinz A, Mann K, Flor H. 2006. Cue exposure in the treatment of alcohol dependence: effects on drinking outcome, craving and self-efficacy. Br J Clin Psychol. 45(Pt 4):515–529.
   PubMedGoogle Scholar
• Lucht MJ, Hoffman L, Haug S, Meyer C, Pussehl D, Quellmalz A, Klauer T, Grabe HJ, Freyberger HJ, John U, et al. 2014. A surveillance tool using mobile phone short message service to reduce alcohol consumption among alcohol-dependent patients. Alcohol Clin Exp Res. 38(6):1728–1736.
   PubMed Web of Science ®Google Scholar
• Maldonado JR. 2010. An approach to the patient with substance use and abuse. Med Clin North Am. 94(6):1169–1205.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar AA, Peindl K, Gorelick DA, Wu L, Gottheil E. 2009. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addict Biol. 14(2):204–213.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar AA, Peindl K, Gottheil E, Wu LT, Gorelick DA. 2009. Early outcomes following low dose naltrexone enhancement of opioid detoxification. Am J Addict. 18(2):109–116.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar AA, Peindl K, Murray HW, Wu LT, Hubbard R. 2007. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. J Clin Psychopharmacol. 27(5):468–474.
   PubMed Web of Science ®Google Scholar
• Manning V, Best D, Faulkner N, Titherington E, Morinan A, Keaney F, Gossop M, Strang J. 2012. Does active referral by a doctor or 12-Step peer improve 12-Step meeting attendance? Results from a pilot randomised control trial. Drug Alcohol Depend. 126(1-2):131–137. doi:https://doi.org/10.1016/j.drugalcdep.2012.05.004.
   PubMedGoogle Scholar
• Manning V, Staiger PK, Hall K, Garfield JB, Flaks G, Leung D, Hughes LK, Lum JA, Lubman DI, Verdejo-Garcia A. 2016. Cognitive bias modification training during inpatient alcohol detoxification reduces early relapse: a randomized controlled trial. Alcohol Clin Exp Res. 40(9):2011–2019.
   PubMed Web of Science ®Google Scholar
• Mark TL, Dilonardo JD, Chalk M, Coffey RM. 2002. Trends in inpatient detoxification services, 1992-1997. J Subst Abuse Treat. 23(4):253–260.
   PubMed Web of Science ®Google Scholar
• Marra D, Warot D, Berlin I, Hispard E, Notides C, Tilikete S, Payan C, Lepine JP, Dally S, Aubin HJ. 2002. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcoholism Clin Exp Res. 26(10):1545–1552.
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Nicola M, De Vita O, Hatzigiakoumis DS, Guglielmo R, Santucci B, Aliotta F, Romanelli R, Verrastro V, Petruccelli F, et al. 2014. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol. 34(6):709–715.
   PubMed Web of Science ®Google Scholar
• McCambridge J, Gossop M, Beswick T, Best D, Bearn J, Rees S, Strang J. 2007. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend. 88(1):91–95.
   PubMed Web of Science ®Google Scholar
• McCarty D, Caspi Y, Panas L, Krakow M, Mulligan DH. 2000. Detoxification centers: who's in the revolving door? J Behav Health Serv Res. 27(3):245–256.
   PubMed Web of Science ®Google Scholar
• McLellan AT, McKay JR, Forman R, Cacciola J, Kemp J. 2005. Reconsidering the evaluation of addiction treatment: from retrospective follow-up to concurrent recovery monitoring. Addict. 100(4):447–458.
   PubMed Web of Science ®Google Scholar
• Meade CS, Lukas SE, McDonald LJ, Fitzmaurice GM, Eldridge JA, Merrill N, Weiss RD. 2010. A randomized trial of transcutaneous electric acupoint stimulation as adjunctive treatment for opioid detoxification. J Subst Abuse Treat. 38(1):12–21.
   PubMed Web of Science ®Google Scholar
• Mills KL, Ewer P, Dore G, Teesson M, Baker A, Kay-Lambkin F, Sannibale C. 2014. The feasibility and acceptability of a brief intervention for clients of substance use services experiencing symptoms of post traumatic stress disorder. Addict Behav. 39(6):1094–1099.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Salomon JA, Mathers CD, Lopez AD, World Health Organization. 2002. Summary measures of population health: Concepts, ethics, measurement and applications. Geneva (Switzerland): World Health Organization.
   Google Scholar
• Myrick H, Taylor B, LaRowe S, Nguyen S, Boyle E, Cochran K, Malcolm R. 2005. A retrospective chart review comparing tiagabine and benzodiazepines for the treatment of alcohol withdrawal. J Psychoactive Drugs. 37(4):409–414.
   PubMed Web of Science ®Google Scholar
• Naderi-Heiden A, Naderi A, Naderi MM, Rahmani-Didar F, Salimi AR, Gleiss A, Kasper S, Frey R. 2010. Ultra-rapid opiate detoxification followed by nine months of naltrexone maintenance therapy in Iran. Pharmacopsychiatry. 43(4):130–137.
   PubMed Web of Science ®Google Scholar
• Ness ML, Oei TP. 2005. The effectiveness of an inpatient group cognitive behavioral therapy program for alcohol dependence. Am J Addict. 14(2):139–154.
   PubMed Web of Science ®Google Scholar
• Nielsen AS, Nielsen B. 2018. Outreach visits improve referral of alcohol dependent patients from psychiatric hospital to continued care. A randomized trial. Nord J Psychiatry. 72(4):303–310.
   PubMed Web of Science ®Google Scholar
• Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. 2006. Behavioral therapy to augment oral naltrexone for opioid dependence: A ceiling on effectiveness? Am J Drug Alcohol Abuse. 32(4):503–517.
   PubMed Web of Science ®Google Scholar
• O'Farrell TJ, Murphy M, Alter J, Fals-Stewart W. 2007. Brief family treatment intervention to promote aftercare among male substance abusing patients in inpatient detoxification: a quasi-experimental pilot study. Addict Behav. 32(8):1681–1691.
   PubMed Web of Science ®Google Scholar
• O'Farrell TJ, Murphy M, Alter J, Fals-Stewart W. 2008. Brief family treatment intervention to promote continuing care among alcohol-dependent patients in inpatient detoxification: a randomized pilot study. J Subst Abuse Treat. 34(3):363–369.
   PubMed Web of Science ®Google Scholar
• Ostergaard M, Jatzkowski L, Seitz R, Speidel S, Weber T, Lubke N, Hocker W, Odenwald M. 2018. Integrated treatment at the first stage: Increasing motivation for alcohol patients with comorbid disorders during inpatient detoxification. Alcohol Alcohol. 53(6):719–727.
   PubMed Web of Science ®Google Scholar
• Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. 2011. Treatment of alcohol dependence with low-dose topiramate: An open-label controlled study. BMC Psychiatry. 11(1):41.
   PubMedGoogle Scholar
• Paparrigopoulos T, Tzavellas E, Karaiskos D, Malitas P, Liappas I. 2010. An open pilot study of tiagabine in alcohol dependence: Tolerability and clinical effects. J Psychopharmacol. 24(9):1375–1380.
   PubMed Web of Science ®Google Scholar
• Pfeifer P, Fehr C. 2019. Efficacy of Varenicline in patients with severe alcohol dependence: A pilot double-blind randomized and controlled study. J Clin Psychopharmacol. 39(4):398–402.
   PubMed Web of Science ®Google Scholar
• R Core Team 2013. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna: Austria. Available from: http://www.R-project.org/
   Google Scholar
• Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. 2020. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: a systematic review and meta-analysis. JAMA Netw Open. 3(6):e208279–e79.
   PubMed Web of Science ®Google Scholar
• Reynaud M, Aubin HJ, Trinquet F, Zakine B, Dano C, Dematteis M, Trojak B, Paille F, Detilleux M. 2017. A randomized, placebo-controlled study of high-dose Baclofen in alcohol-dependent patients-The ALPADIR study. Alcohol Alcohol. 52(4):439–446.
   PubMed Web of Science ®Google Scholar
• Richter C, Effenberger S, Bschor T, Bonnet U, Haasen C, Preuss UW, Heinz A, Forg A, Volkmar K, Glauner T, et al. 2012. Efficacy and safety of levetiracetam for the prevention of alcohol relapse in recently detoxified alcohol-dependent patients: A randomized trial. J Clin Psychopharmacol. 32(4):558–562.
   PubMed Web of Science ®Google Scholar
• Rothman RB, Gorelick DA, Heishman SJ, Eichmiller PR, Hill BH, Norbeck J, Liberto JG. 2000. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abuse Treat. 18(3):277–281.
   PubMed Web of Science ®Google Scholar
• Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Palomo T. 2005. Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol. 40(3):227–233.
   PubMed Web of Science ®Google Scholar
• Saitz R, Cheng DM, Winter M, Kim TW, Meli SM, Allensworth-Davies D, Lloyd-Travaglini CA, Samet JH. 2013. Chronic care management for dependence on alcohol and other drugs: the AHEAD randomized trial. Jama. 310(11):1156–1167.
   PubMed Web of Science ®Google Scholar
• Saitz R, Horton NJ, Larson MJ, Winter M, Samet JH. 2005. Primary medical care and reductions in addiction severity: A prospective cohort study. Addict. 100(1):70–78.
   PubMed Web of Science ®Google Scholar
• Schilling RF, El-Bassel N, Finch JB, Roman RJ, Hanson M. 2002. Motivational Interviewing to encourage self-help participation following alcohol detoxification. Res Soc Work Prac. 12(6):711–730.
   Web of Science ®Google Scholar
• Sewak R, Spielholz NI. 2018. Relapse prevention: Using sound to reduce the probability of recidivism and suffering following detoxification. Med Hypotheses. 118:84–91.
   PubMed Web of Science ®Google Scholar
• Shaw C. 2010. The effectiveness of an innovative model of community opiate detoxification provided on a supported one-to-one basis. J Subst Use. 15(5):340–351.
   Web of Science ®Google Scholar
• Sheard L, Wright NM, El-Sayeh HG, Adams CE, Li R, Tompkins CN. 2009. The Leeds Evaluation of Efficacy of Detoxification Study (LEEDS) prisons project: a randomised controlled trial comparing dihydrocodeine and buprenorphine for opiate detoxification. Subst Abuse Treat Prev Policy. 4:1.
   PubMed Web of Science ®Google Scholar
• Smyth BP, Barry J, Keenan E, Ducray K. 2010. Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J. 103(6):176–179.
   PubMedGoogle Scholar
• Sofuoglu M, DeVito EE, Carroll KM. 2019. Pharmacological and behavioral treatment of opioid use disorder. Psychiatr Res Clin Pract. 1(1):4–15.
   Google Scholar
• Stein M, Herman D, Conti M, Anderson B, Bailey G. 2020. Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial. Addiction. 115(1):82–94.
   PubMed Web of Science ®Google Scholar
• Stein MD, Risi MM, Bailey GL, Anderson BJ. 2016. Linkage to primary care for persons first receiving injectable Naltrexone during inpatient opioid detoxification. J Subst Abuse Treat. 64:44–46.
   PubMed Web of Science ®Google Scholar
• Stensland M, Watson PR, Grazier KL. 2012. An examination of costs, charges, and payments for inpatient psychiatric treatment in community hospitals. Psychiatr Serv. 63(7):666–671.
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Bisaga A, Glass A, Mishlen K, Pavlicova M, Carpenter KM, Mariani JJ, Levin FR, Nunes EV. 2015. Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone. Drug Alcohol Depend. 147:122–129.
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Garawi F, Bisaga A, Comer SD, Carpenter K, Raby WN, Anen SJ, Brooks AC, Jiang H, Akerele E, et al. 2007. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend. 91(2-3):289–292.
   PubMed Web of Science ®Google Scholar
• Timko C, Below M, Vittorio L, Taylor E, Chang G, Lash S, Festin FED, Brief D. 2019. Randomized controlled trial of enhanced telephone monitoring with detoxification patients: 3- and 6-month outcomes. J Subst Abuse Treat. 99:24–31.
   PubMed Web of Science ®Google Scholar
• Timko C, Gupta S, Schultz N, Harris AHS. 2016. Veterans' Service Utilization Patterns After Alcohol and Opioid Detoxification in VHA Care. Psychiatr Serv. 67(4):460–464.
   PubMed Web of Science ®Google Scholar
• Tracy K, Burton M, Nich C, Rounsaville B. 2011. Utilizing peer mentorship to engage high recidivism substance-abusing patients in treatment. Am J Drug Alcohol Abuse. 37(6):525–531.
   PubMed Web of Science ®Google Scholar
• Tuten M, Jones HE, Lertch EW, Stitzer ML. 2007. Aftercare plans of inpatients undergoing detoxification. Am J Drug Alcohol Abuse. 33(4):547–555.
   PubMed Web of Science ®Google Scholar
• Ulrichsen J, Nielsen MK, Ulrichsen M. 2010. Disulfiram in severe alcoholism-an open controlled study. Nord J Psychiatry. 64(6):356–362.
   PubMed Web of Science ®Google Scholar
• Vederhus JK, Timko C, Kristensen O, Hjemdahl B, Clausen T. 2014. Motivational intervention to enhance post-detoxification 12-Step group affiliation: A randomized controlled trial. Addict. 109(5):766–773.
   PubMed Web of Science ®Google Scholar
• Volkow ND, Jones EB, Einstein EB, Wargo EM. 2019. Prevention and treatment of opioid misuse and addiction: A review. JAMA Psychiatry. 76(2):208–216.
   PubMed Web of Science ®Google Scholar
• Weiss AJ, Heslin KC. 2018. Payers of opioid-related inpatient stays and emergency department visits nationally and by state, 2010 and 2015: Statistical Brief# 239. Rockville (MD): Agency for Healthcare Research and Quality.
   Google Scholar
• Wetzel H, Szegedi A, Scheurich A, Lörch B, Singer P, Schläfke D, Sittinger H, Wobrock T, Müller MJ, Anghelescu I, NeVeR Study Group, et al. 2004. Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study. J Clin Psychiatry. 65(10):1406–1413.
   PubMed Web of Science ®Google Scholar
• Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, et al. 2013. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. The Lancet. 382(9904):1575–1586.
   PubMed Web of Science ®Google Scholar
• Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Boening J. 2001. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol. 36(4):329–334.
   PubMed Web of Science ®Google Scholar
• Witkiewitz K, Pearson MR, Wilson AD, Stein ER, Votaw VR, Hallgren KA, Maisto SA, Swan JE, Schwebel FJ, Aldridge A, et al. 2020. Can alcohol use disorder recovery include some heavy drinking? A replication and extension up to 9 years following treatment. Alcohol Clin Exp Res. 44(9):1862–1874.
   PubMed Web of Science ®Google Scholar
• Wright NM, Sheard L, Adams CE, Rushforth BJ, Harrison W, Bound N, Hart R, Tompkins CN. 2011. Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial. Br J Gen Pract. 61(593):e772–e780.
   PubMed Web of Science ®Google Scholar
• Yan L, Liu E, McGoogan JM, Duan S, Wu LT, Comulada S, Wu Z. 2013. Referring heroin users from compulsory detoxification centers to community methadone maintenance treatment: A comparison of three models. BMC Public Health. 13:747.
   PubMed Web of Science ®Google Scholar
• Zaller ND, Thurmond P, Brett J, Carleton JC, Rich JD. 2006. Linkage to methadone treatment from acute opiate detoxification treatment. J Opioid Manag. 2(6):341–346.
   PubMedGoogle Scholar
• Ziaaddini H, Nasirian M, Nakhaee N. 2010. A comparison of the efficacy of buprenorphine and clonidine in detoxification of heroin-dependents and the following maintenance treatment. Addict Health. 2(1-2):18–24.
   PubMedGoogle Scholar
• Zhu H, Wu LT. 2018. National trends and characteristics of inpatient detoxification for drug use disorders in the United States. BMC Public Health. 18(1):1073.
   PubMed Web of Science ®Google Scholar